Real-World Experience of Imipenem–Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study)
Abstract Introduction Difficult-to-treat-resistant (DTR) infections caused by Pseudomonas aeruginosa represent a global public health threat, prioritizing the search and development of new antibiotics for this microorganism. Methods We present the real-life experience of the compassionate use of imi...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2024-11-01
|
| Series: | Infectious Diseases and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40121-024-01077-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571440604381184 |
|---|---|
| author | Isabel Machuca Arantxa Dominguez Rosario Amaya Cristina Arjona Irene Gracia-Ahufinger Maravillas Carralon Rosa Giron Isabel Gea Natividad De Benito Andres Martin Fatima Galan Jose Antonio Martinez Rayden Iglesias Jaume Revuelto Juan Jose Caston Angela Cano Elisa Ruiz-Arabi Luis Martínez-Martínez Julian Torre-Cisneros |
| author_facet | Isabel Machuca Arantxa Dominguez Rosario Amaya Cristina Arjona Irene Gracia-Ahufinger Maravillas Carralon Rosa Giron Isabel Gea Natividad De Benito Andres Martin Fatima Galan Jose Antonio Martinez Rayden Iglesias Jaume Revuelto Juan Jose Caston Angela Cano Elisa Ruiz-Arabi Luis Martínez-Martínez Julian Torre-Cisneros |
| author_sort | Isabel Machuca |
| collection | DOAJ |
| description | Abstract Introduction Difficult-to-treat-resistant (DTR) infections caused by Pseudomonas aeruginosa represent a global public health threat, prioritizing the search and development of new antibiotics for this microorganism. Methods We present the real-life experience of the compassionate use of imipenem/cilastatin/relebactam in a descriptive study involving 14 patients with DTR-P. aeruginosa infection and limited treatment options. Results The primary source of infection was skin and soft tissue infection, 57.1% (8/14), followed by respiratory infection-pneumonia, 28.6% (4/14). At the onset of infection, 71.4% (10/14) of patients were in the intensive care unit (ICU). All our patients had a Charlson Score of ≥ 3. Septic shock was observed in 64.3% (9/14) of patients. The median treatment duration was 15 days, and no patient experienced an adverse event that required treatment interruption. All-cause 30-day mortality was observed in 42.9% of cases (6/14), while clinical efficacy and microbiological success were observed in 64.3% (9/14). Conclusions Imipenem/cilastatin/relebactam may represent a treatment option for patients with DTR-P. aeruginosa infections, which should be validated in prospective clinical trials. |
| format | Article |
| id | doaj-art-4e13983de1b040d5b4527a4ab7248480 |
| institution | Kabale University |
| issn | 2193-8229 2193-6382 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Infectious Diseases and Therapy |
| spelling | doaj-art-4e13983de1b040d5b4527a4ab72484802025-02-02T12:35:26ZengAdis, Springer HealthcareInfectious Diseases and Therapy2193-82292193-63822024-11-0114128329210.1007/s40121-024-01077-zReal-World Experience of Imipenem–Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study)Isabel Machuca0Arantxa Dominguez1Rosario Amaya2Cristina Arjona3Irene Gracia-Ahufinger4Maravillas Carralon5Rosa Giron6Isabel Gea7Natividad De Benito8Andres Martin9Fatima Galan10Jose Antonio Martinez11Rayden Iglesias12Jaume Revuelto13Juan Jose Caston14Angela Cano15Elisa Ruiz-Arabi16Luis Martínez-Martínez17Julian Torre-Cisneros18Infectious Diseases Service, Hospital Universitario Reina SofíaAnesthesiology Service, Hospital Universitario Reina SofíaCritical Care Service, Hospital Universitario Virgen del RocioInstituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)Internal Medicine Service, Hospital Quirón de PozueloPneumology Service, Hospital La PrincesaInfectious Diseases Service, Hospital de JaénInfectious Diseases Service, Hospital Santa Creu y Sant PauInfectious Diseases Service, Hospital Puerta del MarMicrobiology Unit, Hospital Puerta del MarInfectious Diseases Service, Hospital ClinicCritical Care Service, Hospital de GranollersCritical Care Service, Hospital Puerta del MarInfectious Diseases Service, Hospital Universitario Reina SofíaInfectious Diseases Service, Hospital Universitario Reina SofíaInfectious Diseases Service, Hospital Universitario Reina SofíaInstituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)Infectious Diseases Service, Hospital Universitario Reina SofíaAbstract Introduction Difficult-to-treat-resistant (DTR) infections caused by Pseudomonas aeruginosa represent a global public health threat, prioritizing the search and development of new antibiotics for this microorganism. Methods We present the real-life experience of the compassionate use of imipenem/cilastatin/relebactam in a descriptive study involving 14 patients with DTR-P. aeruginosa infection and limited treatment options. Results The primary source of infection was skin and soft tissue infection, 57.1% (8/14), followed by respiratory infection-pneumonia, 28.6% (4/14). At the onset of infection, 71.4% (10/14) of patients were in the intensive care unit (ICU). All our patients had a Charlson Score of ≥ 3. Septic shock was observed in 64.3% (9/14) of patients. The median treatment duration was 15 days, and no patient experienced an adverse event that required treatment interruption. All-cause 30-day mortality was observed in 42.9% of cases (6/14), while clinical efficacy and microbiological success were observed in 64.3% (9/14). Conclusions Imipenem/cilastatin/relebactam may represent a treatment option for patients with DTR-P. aeruginosa infections, which should be validated in prospective clinical trials.https://doi.org/10.1007/s40121-024-01077-zPseudomonas aeruginosaImipenemCilastatinRelebactamCarbapenemResistant |
| spellingShingle | Isabel Machuca Arantxa Dominguez Rosario Amaya Cristina Arjona Irene Gracia-Ahufinger Maravillas Carralon Rosa Giron Isabel Gea Natividad De Benito Andres Martin Fatima Galan Jose Antonio Martinez Rayden Iglesias Jaume Revuelto Juan Jose Caston Angela Cano Elisa Ruiz-Arabi Luis Martínez-Martínez Julian Torre-Cisneros Real-World Experience of Imipenem–Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study) Infectious Diseases and Therapy Pseudomonas aeruginosa Imipenem Cilastatin Relebactam Carbapenem Resistant |
| title | Real-World Experience of Imipenem–Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study) |
| title_full | Real-World Experience of Imipenem–Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study) |
| title_fullStr | Real-World Experience of Imipenem–Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study) |
| title_full_unstemmed | Real-World Experience of Imipenem–Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study) |
| title_short | Real-World Experience of Imipenem–Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study) |
| title_sort | real world experience of imipenem relebactam treatment as salvage therapy in difficult to treat pseudomonas aeruginosa infections imrecor study |
| topic | Pseudomonas aeruginosa Imipenem Cilastatin Relebactam Carbapenem Resistant |
| url | https://doi.org/10.1007/s40121-024-01077-z |
| work_keys_str_mv | AT isabelmachuca realworldexperienceofimipenemrelebactamtreatmentassalvagetherapyindifficulttotreatpseudomonasaeruginosainfectionsimrecorstudy AT arantxadominguez realworldexperienceofimipenemrelebactamtreatmentassalvagetherapyindifficulttotreatpseudomonasaeruginosainfectionsimrecorstudy AT rosarioamaya realworldexperienceofimipenemrelebactamtreatmentassalvagetherapyindifficulttotreatpseudomonasaeruginosainfectionsimrecorstudy AT cristinaarjona realworldexperienceofimipenemrelebactamtreatmentassalvagetherapyindifficulttotreatpseudomonasaeruginosainfectionsimrecorstudy AT irenegraciaahufinger realworldexperienceofimipenemrelebactamtreatmentassalvagetherapyindifficulttotreatpseudomonasaeruginosainfectionsimrecorstudy AT maravillascarralon realworldexperienceofimipenemrelebactamtreatmentassalvagetherapyindifficulttotreatpseudomonasaeruginosainfectionsimrecorstudy AT rosagiron realworldexperienceofimipenemrelebactamtreatmentassalvagetherapyindifficulttotreatpseudomonasaeruginosainfectionsimrecorstudy AT isabelgea realworldexperienceofimipenemrelebactamtreatmentassalvagetherapyindifficulttotreatpseudomonasaeruginosainfectionsimrecorstudy AT natividaddebenito realworldexperienceofimipenemrelebactamtreatmentassalvagetherapyindifficulttotreatpseudomonasaeruginosainfectionsimrecorstudy AT andresmartin realworldexperienceofimipenemrelebactamtreatmentassalvagetherapyindifficulttotreatpseudomonasaeruginosainfectionsimrecorstudy AT fatimagalan realworldexperienceofimipenemrelebactamtreatmentassalvagetherapyindifficulttotreatpseudomonasaeruginosainfectionsimrecorstudy AT joseantoniomartinez realworldexperienceofimipenemrelebactamtreatmentassalvagetherapyindifficulttotreatpseudomonasaeruginosainfectionsimrecorstudy AT raydeniglesias realworldexperienceofimipenemrelebactamtreatmentassalvagetherapyindifficulttotreatpseudomonasaeruginosainfectionsimrecorstudy AT jaumerevuelto realworldexperienceofimipenemrelebactamtreatmentassalvagetherapyindifficulttotreatpseudomonasaeruginosainfectionsimrecorstudy AT juanjosecaston realworldexperienceofimipenemrelebactamtreatmentassalvagetherapyindifficulttotreatpseudomonasaeruginosainfectionsimrecorstudy AT angelacano realworldexperienceofimipenemrelebactamtreatmentassalvagetherapyindifficulttotreatpseudomonasaeruginosainfectionsimrecorstudy AT elisaruizarabi realworldexperienceofimipenemrelebactamtreatmentassalvagetherapyindifficulttotreatpseudomonasaeruginosainfectionsimrecorstudy AT luismartinezmartinez realworldexperienceofimipenemrelebactamtreatmentassalvagetherapyindifficulttotreatpseudomonasaeruginosainfectionsimrecorstudy AT juliantorrecisneros realworldexperienceofimipenemrelebactamtreatmentassalvagetherapyindifficulttotreatpseudomonasaeruginosainfectionsimrecorstudy |